Ms. Varanasi is a co-founder, President and CEO of X-Biotix. She is an accomplished business executive, with 24 years of biopharmaceutical industry experience and a distinguished track record in structuring, negotiating and executing successful strategic alliances, licensing agreements and M&A transactions as well as providing business development, management and strategic leadership to organizations. She has held Research and senior level positions in Business & Corporate Development including at Merck, Millennium (now Takeda), Momenta, and Checkmate Pharmaceuticals, to name a few. Over the course of her career, Ramani has been involved in the formation of strategic partnerships with companies and research organizations globally, including in emerging markets such as Asia - and continues to have a keen interest in bridging the research and business gap and fostering collaboration between enterprises in this global marketplace. Her broad experience in the areas of early stage company formation and financing, including dilutive and non-diluting funding initiatives, has enabled her to execute deals with total value in excess of several billion dollars. Ramani holds a B.Sc. and a M.Sc. from McGill University in Microbiology & Immunology and Biochemistry, respectfully, and an MBA in General Strategy from Northeastern University. She volunteers as a mentor to start-up companies in the biopharma area and also has an avid interest in the area of international healthcare, a sector in which she has been involved as a board member for two non-profit organizations.

Dr. Ryan serves as the Chief Scientific Officer at X-Biotix. He holds a Ph.D. in organic chemistry from McGill University and conducted postdoctoral work at Cornell University. Dominic brings 30 years of experience in drug discovery from medicinal chemistry and structural biology to computational and biophysical methods to high throughput screening. He held positions of increasing seniority at Millennium, GSK and most recently at Cubist, where he built and led Discovery Technologies, was co-head of Medicinal Chemistry, was a member of Cubist’s research management team, and where he also won the CSO award for innovation. In addition, while at Cubist, he led teams working on inflammation and neuroscience in addition to antibacterial research and helped advance their clinical candidates, including Zerbaxa. Throughout his career, Dominic has contributed to technology and drug research diligence within companies and for investment groups. More recently he has advised a number of companies, primarily in the antibacterial space, and also serves as member of the Scientific Advisory Board of Carb-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator), an organization promoting antibiotic research with competitive funding to advance antibiotic development programs.

Dr. David Huang is serving as the Chief Medical Officer for X-Biotix Therapeutics. He has previously served as a faculty member at Baylor College of Medicine and is currently an adjunct Assistant Professor at Rutgers New Jersey Medical School. He is responsible for and experienced in designing, executing and closing out Phase I – III clinical trials for both antibacterials and antiviral agents. David served as the Chief Medical Officer at Motif BioSciences from 2014-2019, where he was responsible for leading the clinical development, regulatory strategy and medical affairs functions for an antibacterial agent, iclaprim. Prior to Motif BioSciences, David served as the Chief Medical Officer and headed the clinical development and regulatory strategy of numerous antinfective programs at ContraFect including bacteriophage endolysins for S. aureus bacteremia. Prior to ContraFect, David served as the Senior Director of Pfizer, where he was responsible for the regulatory and commercial strategy and medical affairs functions for an antibacterial agent, linezolid. David completed his medical school at the University of Texas at Houston Medical School, and completed his internship and residency in internal medicine at the University of Texas at Southwestern and fellowship in infectious diseases at Baylor College of Medicine. He is board-certified in both internal medicine and infectious diseases. Dr. Huang has published over 100+ peer reviewed papers and chapters in the field of infectious diseases.

Mr. Beloff serves as Chief Financial Officer at X-Biotix, and applies more than 20 years of experience in the life science and technology industries, ranging from venture-backed start-ups to publicly traded companies. He previously served as CFO of two public and three privately held companies, during which time he managed finance, accounting, corporate communications, human resources, information technology, facilities, legal, intellectual property, business development and manufacturing functions. Gregg’s core expertise includes operational management, strategic planning and corporate and business development, fundraising and mergers and acquisitions. Prior to his CFO roles, Gregg was a life science investment banker with Adams, Harkness & Hill, where he underwrote financings for and provided buy- and sell-side M&A counsel to biotechnology, medical device, and healthcare information technology companies. He began his career as a corporate attorney with Gaffin & Krattenmaker, a Boston-based law firm. Gregg holds a BA from Middlebury College, JD from the University of Pittsburgh School of Law and MBA from Carnegie Mellon University.

Dr. DeJonge obtained his Ph.D. in Microbial Physiology at the University of Amsterdam (the Netherlands), and did his post-doctoral work at The Rockefeller University (New York, NY, USA), where he studied the biochemical mechanisms of methicillin resistance in Staphylococcus aureus and vancomycin resistance in Enterococci. This work led to an appointment as research assistant-professor. Subsequently, Boudewijn joined AstraZeneca (then called Astra Research Center Boston) and was involved in the studies related to the discovery of selective therapy against Helicobacter pylori, which over time were extended to the discovery and development of broad-spectrum anti-bacterials. He led multi-disciplinary teams, as well as a specialized group that was responsible for all in vitro microbiology assays and worked on the development of the β-lactam/β-lactamase combinations ceftazidime-avibactam and aztreonam-avibactam. In addition, Dr. DeJonge oversaw a worldwide microbiology surveillance program that assessed the activity of antibiotics in development and antimicrobial resistance for marketed antibiotics. Upon the acquisition of the small molecule anti-infectives portfolio from AstraZeneca by Pfizer, Boudewijn joined Pfizer where he continued to work on the development of aztreonam-avibactam and the microbiology surveillance study. Over his career, he has amassed a broad range of experiences at all stages of antibacterial drug discovery and development, from target selection to hit identification and lead optimization, and extending to late-stage clinical development, including Phase 3 clinical trials. Dr. DeJonge’s contributions have been published in several peer-reviewed journals, and he currently serves on the editorial board of Antimicrobial Agents and Chemotherapy and Microbial Drug Resistance.

Ms. Moore is serving as Head of Portfolio Management and Business Operations at X-Biotix. In the last 14 years, she's been involved in all stages of a pharmaceutical product’s lifecycle, from pre-clinical to commercialization, leading and executing across functional disciplines. Prior to joining the pharmaceutical industry, Lorien spent 10 years working in global consumer products companies, with roles in finance, marketing, and sales. Lorien’s anti-infective experience includes 8 years at Cubist Pharmaceuticals where she was the commercial leader on Zerbaxa’s program team during phase 2 and phase 3 development. Other roles included head of alliance management, international expansion project management, and various commercial positions. Over her tenure at Cubist, Lorien was involved in commercialization and development of Cubist’s entire antibiotic portfolio, including Cubicin, Dificid, Sivextro, Zerbaxa and a co-promotion of Merrem. Lorien’s most recent experience was at Flexion Therapeutics where she was responsible for commercial strategy and market development for Flexion’s pipeline assets and in-licensing/out-licensing opportunities. Additionally, she gained experience with microbiome therapeutics as head of alliance management at Seres Therapeutics. Lorien holds a B.A. from the University of Illinois and an MBA from the MIT Sloan School of Management.

Ms. Roth serves as the Operations Manager at X-Biotix. She has professional experience in multiple industries including biotechnology, information technology, and the performing arts. Megan has 18 years of experience in successfully operationalizing startup companies, both in the profit and nonprofit sectors. Her range of experience spans the areas of operations, program and project management, building strategic partnerships, and executive administration. Prior to joining X-Biotix, Megan served as the Senior Sales and Accounting Specialist for a startup managed service provider in the information technology field. She is passionate about working in dynamic and engaging startup companies and is driven by the desire to help companies build and grow. Megan holds an undergraduate degree in music performance from DePaul University in Chicago and a Master of Music degree from the Florida State University.

Maura Snow, Human Resources for X-Biotix, is an experienced consultant with 20 years' experience providing senior level HR services for small startup companies, as well as project-based assignments for established HR functions that require a short-term focus on specific initiatives. She has partnered with CEO’s and senior leaders to establish and maintain a work environment where the achievement of key business objectives is standard operating procedure for all. Maura has received accolades for her leadership team building and goal setting strategies. Additionally, Maura holds Certification in Insights Discovery and Deeper Discovery, which provides clients with access to the tools and experiences necessary to achieve the personal breakthroughs that lead to business breakthroughs. Maura holds a Master’s Degree in Public Administration from Brigham Young University.

Mr. Isaacs has served as the Chairman of X-Biotix’s Board of Directors since April 2018. He has more than 40 years of corporate leadership and scientific management experience within the biopharmaceutical sector, and has served as the Chairman, President & CEO of Aduro Biotech, Inc. since 2008. Prior to Aduro, Steve founded Cerus Corporation in 1991, a biomedical products company commercializing the Intercept Blood Systems. The Intercept systems are now globally available and used to prevent a variety of diseases from blood transfusion. He served as President and Chief Executive Officer of Cerus from 1991 to 2004. Prior to Cerus, Steve founded and served as Chief Executive Officer and President of HRI Associates and HRI Research, both biotechnology companies focusing on research and development in various areas. He held a non-teaching faculty position in the Department of Chemistry at the University of California Berkeley from 1978 to 1986. Mr. Isaacs has published over 20 peer-reviewed scientific articles and is an inventor on over 40 issued patents.

In addition to leading multiple biotechnology companies, Steve has spent considerable time on the African continent working on various non-profit activities. With his family, he founded “A Better Education” (ABE) Club, which provides educational opportunities, microfinance training and healthcare for remote villagers in the south of Kenya.  More recently, he founded the Alliance for Global Health and Science with the Department of Public Health at UC Berkeley, which undertakes capacity building at universities and medical schools in Uganda and Zimbabwe.  He also established the Immunotherapeutics and Vaccine Research Initiative at UC Berkeley, which is an Aduro-sponsored campus-wide organization to promote immunological research for cancer and infectious disease, and has been widely recognized in the industry as an innovator and leader, forging deep ties between biotech and academia with the goal of discovering breakthrough technologies to make an impact on global health. Steve holds an undergraduate degree in biochemistry from the University of California at Berkeley, where he also pursued Ph.D. studies in organic chemistry.

Mr. Ray serves as a Director on X-Biotix’s Board of Directors. He has over 20 years of experience in private equity and in working closely with many start-ups and growth companies, including in the roles of investor, advisor, and Board member. Christopher is currently an Advisory Partner in the private equity firm NGP Energy Capital Management, where he has held various positions over the past 15 years in roles including firm management, investment evaluation, portfolio management, and transaction structuring and negotiation for NGP’s portfolio companies. Prior to joining NGP, he was a Partner in the law firm of Thompson & Knight, LLP. He practiced in the Corporate and Securities group in Dallas for approximately eight years, working on hundreds of investment and corporate financing transactions, including the formation and capitalization of investment funds, portfolio company investments and exits, mergers and acquisitions, securities law compliance and public and private debt and equity offerings. Christopher received a B.S. in Accounting with distinction in 1992 and a J.D. in 1995, both from The University of Virginia.

Dr. Cook serves as a Director on X-Biotix’s Board of Directors. He is a scientist and entrepreneur who has held senior operating and management positions in the biotechnology industry over his 25-year career. David has led teams to develop and commercialize biotech products and has been directly responsible for obtaining marketing authorization for four novel medical products. As CSO at Seres Therapeutics, a leading company in the field of microbiome therapeutics, a position which he held from 2012 to date 2019, David played a key role in the strategy and fund raising for the company and was integral to the translation to the clinic of drugs for C. difficile, Inflammatory Bowel Disease and Immuno-Oncology. Prior to joining Seres, Dr. Cook was the Chief Operating Officer for the International AIDS Vaccine Initiative (IAVI), a global R&D organization whose mission is to develop a safe, effective and globally accessible vaccine for HIV. Prior to his role at IAVI, David was the founding CEO at Anza Therapeutics, a start-up developing a novel microbial vaccine platform to induce cellular immune responses to fight or prevent cancer and chronic infections. At Anza, Dr. Cook raised venture capital and non-dilutive funding from governmental and nonprofit sources and led a team that moved three novel immunotherapy candidates into clinical trials. Before launching Anza, David held positions of increasing responsibility at the biotechnology corporations Cerus and Eligix, with oversight over R&D, program management, manufacturing, and clinical and regulatory affairs. He is also a co-inventor on over twenty-five patents. Dr. Cook received his undergraduate degree from Harvard College and his Ph.D. in chemistry from the University of California, Berkeley.

Ms. Varanasi is a co-founder, President and CEO of X-Biotix. She is an accomplished business executive, with 24 years of biopharmaceutical industry experience and a distinguished track record in structuring, negotiating and executing successful strategic alliances, licensing agreements and M&A transactions as well as providing business development, management and strategic leadership to organizations. She has held Research and senior level positions in Business & Corporate Development including at Merck, Millennium (now Takeda), Momenta, and Checkmate Pharmaceuticals, to name a few. Over the course of her career, Ramani has been involved in the formation of strategic partnerships with companies and research organizations globally, including in emerging markets such as Asia - and continues to have a keen interest in bridging the research and business gap and fostering collaboration between enterprises in this global marketplace. Her broad experience in the areas of early stage company formation and financing, including dilutive and non-diluting funding initiatives, has enabled her to execute deals with total value in excess of several billion dollars. Ramani holds a B.Sc. and a M.Sc. from McGill University in Microbiology & Immunology and Biochemistry, respectfully, and an MBA in General Strategy from Northeastern University. She volunteers as a mentor to start-up companies in the biopharma area and also has an avid interest in the area of international healthcare, a sector in which she has been involved as a board member for two non-profit organizations.

Mike Bonney is Executive Chair of Kaleido Biosciences’ Board of Directors. Previously, Bonney was CEO and Director of Cubist Pharmaceuticals from 2003 until 2014. Under his leadership, Cubist grew from a struggling micro-cap to the world’s leading antibiotic company, and was acquired by Merck early in 2015 for $9.5 billion. Prior to Cubist, Bonney was Vice President of Sales and Marketing at Biogen where he built the company’s commercial infrastructure for the launch of its first product. Before joining Biogen, he spent 11 years at Zeneca Pharmaceuticals in a range of commercial, operating and strategic roles, ending his career there as National Business Director.

Bonney also chairs the boards of Alnylam Pharmaceuticals and Magenta Therapeutics.  He is a member of a number of other boards, including Celgene Corporation, Sarepta Therapeutics, and Syros Therapeutics.  Bonney spends much of his time identifying and mentoring the next generation of life science leaders.

Bonney was a regional winner and national finalist (2013) in the life science segment of Ernst & Young’s Entrepreneur of the Year and was one of six executives nationwide named as Marketwatch’s CEO of the Year (2011). He received his undergraduate degree in economics from Bates College.

Dr. Dougherty received his Ph.D. in Microbiology from Thomas Jefferson University, Philadelphia, PA.  He spent 8 years at the Rockefeller University Alexander Tomasz’s laboratory, working on NIH funded studies of the role of Neisseria gonorrhoeae penicillin binding proteins in antibiotic mechanism of action and beta-lactam resistance. Tom has over 25 years of experience in the pharmaceutical industry in the antibiotic R&D groups at Bristol-Myers Squibb, Pfizer, and AstraZeneca. His lab was engaged in work that supported drug discovery, including microbial genetics & physiology, high throughput screening, and antibiotic mechanisms of action and mechanisms of resistance.  In his industrial roles, Dr. Dougherty worked on cefepime, cefprozil, garenoxicin, and a number of early stage discovery programs for novel antibiotics, and while at Pfizer, wrote the pre-clinical pharmacology section of the IND for a novel ketolide that entered Phase I.  At AstraZeneca, in addition to his laboratory leader role, he was part of the Antibiotic Leadership Team.  He has spent the past 5 years in Professor Steve Lory’s lab in the Department of Microbiology & Immunobiology Harvard Medical School researching compounds that inhibit the lipoprotein pathway in the periplasm, in an attempt to pharmacologically compromise the outer membrane integrity of Gram-negative bacteria. Tom has served on the Editorial Board of Antimicrobial Agents and Chemotherapy for the past 14 years, and was a contributor to the 2015 Pew Trust Report on “A Roadmap for Antibiotic Discovery”.  He serves on the Scientific Advisory Board of Macrolide Pharmaceuticals, and is a reviewer for applications to Carb-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator), an organization promoting antibiotic research with competitive funding to advance antibiotic development programs.

Dr. Gobec is Professor of Pharmaceutical Chemistry and the Head of the Department of Pharmaceutical Chemistry in the Faculty of Pharmacy at the University of Ljubljana in Slovenia. Dr. Gobec received both his M.Sc. in Pharmacy and a Ph.D. in the field of Medicinal Chemistry from the University of Ljubljana. His specific research interests include structure-based in-silico design, synthesis and evaluation of small-molecule enzyme inhibitors, agents acting on central nervous system, inhibitors of bacterial cell wall biosynthesis, anti-tumour agents, and synthesis of mimetics of natural compounds, including peptidomimetics, glycomimetics, lipidomimetics. Stanislav’s areas of expertise include drug discovery, medicinal and pharmaceutical chemistry, in-silico drug design, virtual high-throughput screening, enzyme inhibitors, and organic chemistry and molecular pharmacology. From 2007 to 2011, he was a Dean in the Faculty of Pharmacy, and a member of the Ljubljana Senate – and during his tenure at the University of Ljubljana, has engaged in a collaboration with a multi-national pharmaceutical company on aspects of ongoing research effors in his lab. Dr. Gobec has been an author or co-author on more than 180 publications in important peer-reviewed journals and has several granted patents and patent applications. He has also written two comprehensive book chapters in Houben-Weyl Science of Synthesis and has given multiple interviews for the popularization of science.

Dr. Pollastri earned his bachelor’s degree from the College of the Holy Cross, a master’s degree from Duke University and his doctorate from Brown University. Following completion of his master’s degree in 1998, he joined Pfizer Global Research & Development, earning his Ph.D. while moving up the ranks within the medicinal chemistry organization, eventually leading the Chemical Technologies group at the Research Technology Center in Cambridge, MA. Michael remained with Pfizer until 2007, when he accepted a research faculty position in the Boston University Department of Chemistry. There, he led the establishment of the Center for Molecular Discovery, a University resource that encompassed a combination of high-throughput screening and medicinal chemistry optimization capabilities. In 2009, he joined the faculty in the Department of Chemistry and Chemical Biology at Northeastern University, where his research has been focused on discovery of new therapeutics for infectious diseases. Dr. Pollastri was appointed department chair in 2016 and promoted to full professor in 2017, and in addition, currently serves as the interim director of the Barnett Institute of Chemical and Biological Analysis.

Dr. Robins is an instructor in the Microbiology Department at Harvard Medical School. He received his Ph.D. degree in Molecular Biology at the University of Texas at Austin in 2008 while studying bacteriophage biology and the role of bacterial transcription. In 2009, Bill joined the John Mekalanos laboratory as a postdoctoral fellow at Harvard Medical School to study Vibrio cholerae infection and spent much of this training investigating the genomics of V.cholerae epidemic strains, virulence gene expression, and bacterial genes that confer a fitness advantage in the microbial community. He is a molecular biologist and bacterial geneticist with training in bioinformatics. Much of his current research focuses on Gram-negative pathogenic bacteria and identifying key interactions between pathogens and both the host and other bacteria in the microbiome using genomics and high-throughput genetic screens. Other tangential projects focus on the interrogation of antibiotic resistant proteins using peptides and mutagenic screens to develop novel strategies for developing new antibacterial molecules. Bill advocates that these methodologies that identify new important interactions and decipher their molecular mechanisms will reveal additional and even nonintuitive targets for future drug discovery.

Helen Boucher is the Chief of the Division of Geographic Medicine and Infectious Diseases and Director of the Tufts Center for Integrated Management of Antimicrobial Resistance (CIMAR), a collaborative, cross-disciplinary initiative between Tufts University and Tufts Medical Center with a mission of innovating to protect humanity from the global threat of antimicrobial resistance by integrating solutions across human and veterinary medicine, stewardship and awareness. She is Director of TMC’s Heart Transplant and Ventricular Assist Device Infectious Diseases Program, and Professor of Medicine at Tufts University School of Medicine.

Dr. Boucher’s clinical interests include infections in immunocompromised patients and S. aureus infections.  Her research interests focus on S. aureus and the development of new anti-infective agents.  She is the author or coauthor of numerous abstracts, chapters, and peer-reviewed articles, which have been published in such journals as The New England Journal of Medicine, Antimicrobial Agents and Chemotherapy, Clinical Infectious Diseases, and The Annals of Internal Medicine; she is Associate Editor of Antimicrobial Agents and Chemotherapy.

In 2015, Dr. Boucher was appointed a voting member of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria, and elected Treasurer of the Infectious Diseases Society of America.  She was awarded the IDSA Society Citation Award in October, 2015.  Dr. Boucher serves on the Board of Trustees of The College of the Holy Cross and as Chair of the Board of Trustees of the Physicians of Tufts Medical Center.

Lynda Berne is founder of BAL Pharma Consulting, LLC, a Princeton, NJ Management Consulting firm providing Commercial Advisory Services to Biotech and Specialty Pharma.Lynda has held several senior and executive roles in pharma encompassing broad commercial experience and including 13 years at Bristol-Myers Squibb where she held the roles of Vice President, Infectious Disease Marketing, managing a $600M business unit and Vice President, Managed Health Care Sales. Other senior commercial positions held include General Manager, Hospital/CV Portfolio, a $1B business unit, Abbott International, and Executive Director, Gastroenterology/Nephrology Marketing, a $200M business unit, Shire Pharmaceuticals. Lynda has a BS in Nursing from Indiana University, an MS in Nursing from DePaul University and an MBA from Northwestern University, Kellogg Graduate School of Management.

Patricia A. Bradford is the owner of Antimicrobial Development Specialists LLC, a consulting company that focuses on the late stage development of antibiotics. Prior to this she was at AstraZeneca and was responsible for the microbiology support contributing to the successful development and approval of ceftazidime-avibactam. Before joining AstraZeneca, Dr. Bradford worked in antibiotic research for Novartis, Wyeth Pharmaceuticals and Lederle Laboratories. During her tenure at Wyeth she worked on a number of antibiotic projects and was instrumental in the team that wrote the dossier for the registration and approval of tigecycline.  She was also heavily involved in the studies for several sNDA applications for piperacillin-tazobactam.  Dr. Bradford is fellow in the American Academy of Microbiology, has over 95 publications in peer-reviewed scientific journals and has written several review articles and book chapters.  She served as an editor for Antimicrobial Agents Chemotherapy 2001-2011 and is currently a Senior Editor for ASM’s newest journal, mSphere. She is also an active member of the subcommittee on Antimicrobial Susceptibility Testing of the Clinical Laboratory Standards Institute.  Prior to working industry, she worked as a clinical microbiologist at Nebraska Methodist Hospital in Omaha.  Dr. Bradford received a B.S. in Medical Technology from the University of Nebraska Medical School, Ph.D. in Medical Microbiology from Creighton University and completed a post-doctoral fellowship in the laboratory of Dr. Karen Bush in b-lactamase research.

Dr. Echols is an Infectious Disease trained physician and Principal of Infectious Disease Drug Development Consulting, LLC, a consulting firm established in 2008 focused on the development of anti-microbial therapies including drugs, biologics and devices.  Dr. Echols has extensive experience in the development of anti-bacterial, anti-viral and antifungal drugs both in the US and internationally. His industry career started in 1989 as Medical Director at Bayer leading the US development of ciprofloxacin. He was Medical Director at Immunex Corporation (GmCSF) from 1996 to 1997 and Vice President of Infectious Disease Clinical Research and Development at Bristol Myers Squibb from 1997-2004 (gatifloxacin, garenoxacin, atazanavir (HIV), ravuconazole and entecavir [HBV]). He served as Chief Medical Officer of Replidyne, Inc (faropenem) from 2005-2008 helping to take the company public in 2007.

As a consultant he has explored novel antimicrobial projects including biologics and devices, as well as more traditional antibiotics that address targets defined as Urgent by CDC and the biodefense community.

Dr. Echols has had numerous opportunities to interact with the FDA and EMA, including public workshops and advisory committee presentations. Most recently, he represented Shionogi in the successful discussion of cefiderocol (14-2 committee vote) in October 2019.

Prior to joining the pharmaceutical industry, Dr. Echols was Head of the Division of Infectious Diseases at Albany Medical College and an attending physician at Albany Medical Center. Dr. Echols holds a B.A. from Yale University and an M.D. from Tufts University School of Medicine and completed his Infectious Diseases training at the University of New Mexico. He is a Fellow in the Infectious Disease Society of America.

Dr. Echols has more than 100 peer review publications, most involving anti-infective research and clinical development.

Dr. Friedland is currently a consultant, focusing on advising companies on early and late-stage development of anti-infective products. He completed his general medical and pediatric training in South Africa (University of the Witwatersrand, Johannesburg) and completed his pediatric infectious disease fellowship at UT Southwestern Medical Center in Dallas. Ian served as the chief medical officer at Achaogen from 2014 to 2017, where he was responsible for leading the clinical development, regulatory strategy and medical affairs functions. As CMO and consultant he led the successful filing of Plazomicin. Prior to Achaogen, Dr. Friedland headed the clinical development of numerous antibiotics at Cubist pharmaceuticals. He has worked in the pharmaceutical and biotechnology industry for 20 years, at both large Pharma (Merck, Johnson & Johnson) and several small biotech companies, leading clinical development teams of several important antibiotics and has played a pivotal role in the development and regulatory submission in the US, EU and other regions of new drugs including ertapenem, caspofungin, doripenem, alvimipan, fidaxomicin, ceftolozane/tazobactam and plazomicin, in addition to supporting many marketed anti-infective agents. Ian is a frequent participant in FDA/FNIH/PhRMA infectious disease working groups and is an author on over 100 peer reviewed journal articles and book chapters.

Dr. Lodise, Pharm.D., Ph.D., is Professor at Albany College of Pharmacy and Health Sciences, Albany, New York. He is also an infectious diseases clinical pharmacy specialist at the Stratton VA Medical Center, Albany, New York. Integrating his dual interests in research and patient care, his overall research goal is to quantitatively enhance our current understanding of antimicrobial exposure-response relationships in patients with invasive bacterial infections. Tom’s research encompasses three interrelated domains: pharmacokinetics (PK)/pharmacodynamics (PD), epidemiology, and outcomes.  He has published over 140 peer-reviewed articles in numerous medical and pharmacy journals. He is a scientific editor for Pharmacotherapy and is an editorial board member for Antimicrobial Agents and Chemotherapy and Diagnostic Microbiology and Infectious Diseases. Dr. Lodise is also a member of the vancomycin consensus guideline committee and is the current chair of the PK Special Emphasis Panel for the Antibacterial Resistance Leadership Group (ARLG) (https://arlg.org), an initiative funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).

Dr. Mekalanos is a professor at Harvard Medical School and has served as chair of the Department of Microbiology and Immunobiology (formerly Microbiology and Molecular Genetics) for twenty years (1996-2016).  He is a co-founder of X-Biotix and Chair of its Scientific Advisory Board.  John received his Ph.D. at the University of California in 1978 and after postdoctoral training at Harvard joined its faculty in 1981. His research investigates multiple facets of bacterial pathogenesis, with an emphasis on using functional genomics to explore pathogen-host interactions, virulence regulation, and antibiotic target identification. One of the important practical benefits of this research has been the development of live attenuated vaccines effective against cholera and the discovery of the first anti-virulence drug (virstatin).  He was elected to the National Academy of Sciences in 1998 and has received many honors, including the Eli Lilly Award (1991), AAAS Newcomb Cleveland Prize (1993), the City of Medicine Award (1997), Drexel Medicine Prize in Infectious Disease (2012), and the Sanofi-Institut Pasteur Award for Biomedical Research (2012).  Dr. Mekalanos has been a member of the FDA Advisory Committee on Vaccines and Related Biologics and has also advised numerous governmental and private agencies including the National Institutes of Health, the World Health Organization, U.S. Department of Defense, U.S.-Japan Cooperative Medical Science Program, and the Ragon Institute.  He has been an active consultant in the pharmaceutical industry, and served as head of microbiology at Vicuron just prior to its purchase by Pfizer.  John has co-founded two biotechnology firms that are now publicly traded, including Avant Immunotherapeutics and PharmAthene, and was sole scientific founder of Matrivax, a vaccine research and development company that recently completed a successful Phase I trial on novel technology he invented at Harvard.

Dr. Lory is a scientific co-founder and a member of X-Biotix’s Scientific Advisory Board, and has been a Professor of Microbiology at Harvard Medical School since 2000. He received his Ph.D. in Microbiology (UCLA) in 1980, and spent four years at the postdoctoral fellow at Harvard Medical School, before joining the faculty at the University of Washington in Seattle where he remained for 15 years. Steve was the recipient of a MERIT Award from the NIH, a Fulbright Fellowship and was a Research Scholar of the Cystic Fibrosis Foundation. Throughout his academic career, he has worked on various topics related to infections caused by the opportunistic human pathogen Pseudomonas aeruginosa and directed research projects in virulence, antibiotic resistance, host response and genome evolution of this organism. Additional projects in Dr. Lory’s laboratory include work on regulatory networks active during infection both at the transcriptional and post-transcriptional levels. In addition to continuing his work on non-coding small RNAs, the lab is also involved in the development of new anti-Pseudomonas drugs targeting outer membrane biogenesis of Gram-negative bacteria and their efflux pumps. Steve has served on the advisory committees of several research funding agencies including the NIH and the Cystic Fibrosis Foundation and was a member of the Institut Pasteur’s Scientific Council. He has been also a consultant to several biotechnology and pharmaceutical companies. Over the course of the past 30 years, Dr. Lory has trained numerous students and post-doctoral fellows who are currently independent investigators at universities or are team leaders in biotechnology companies.

Dr. Bernhardt is a scientific co-founder of X-Biotix and a member of the company’s Scientific Advisory Board. Tom is an Investigator of the Howard Hughes Medical Institute based in the Department of Microbiology and Immunobiology at Harvard Medical School, where he studies the mechanisms of cell wall assembly in both Gram-negative and Gram-positive bacteria. Work in the Bernhardt lab has provided fundamental insights into the process of cell wall biogenesis and how best to target the process for antibiotic development. He is a molecular geneticist by training with additional expertise in bacterial cell biology and cell wall biochemistry. Tom received his Ph.D. in Biochemistry and Biophysics from Texas A&M University and performed postdoctoral studies at Case Western Reserve University. He has received multiple awards for his research, including the Nat Sternberg Thesis Prize, a Career Award in the Biomedical Sciences from the Burroughs Wellcome Fund, and a Howard Hughes Medical Institute/Simons Foundation Faculty Scholar Award. In addition to his academic research, Dr. Bernhardt has had a long-standing interest in antibiotic development and has consulted for or collaborated with several industry groups in this area before joining the X-Biotix team.